

Case Report Section

Paper co-edited with the European LeukemiaNet

A case of sole i(4)(p10) in myelodysplastic syndrome

François Desangles, Aurélie Servonnet, Hubert Nielly, Serge Cremades, Jean-Etienne Pilo

Laboratoire de Biologie Médicale, HIA Val de Grace, 74bd Port-Royal, F 75005 Paris, France (FD, AS),
Médecine - Oncologie, HIA Begin, 69 ave de Paris, F 94160 Saint Mandé, France (HN, SC), Laboratoire de
Biologie Médicale, HIA Begin, 69 ave de Paris, F 94160 Saint Mandé, France (JEP)

Published in Atlas Database: July 2013

Online updated version : <http://AtlasGeneticsOncology.org/Reports/i4p10DesanglesID100073.html>
DOI: 10.4267/2042/53090

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2014 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract

Case report on a case of sole i(4)(p10) in myelodysplastic syndrome.

Clinics

Age and sex

79 years old male patient.

Previous history

No preleukemia, previous malignancy (the patient had an acute myeloid leukemia (AML) of unknown type, 20 years ago), no inborn condition of note.

Organomegaly

No hepatomegaly, no splenomegaly, no enlarged lymph nodes, no central nervous system involvement.

Blood

WBC: 2.7 X 10⁹/l

HB: 9.7g/dl

Platelets: 73 X 10⁹/l

Blasts: 0%

Bone marrow: Hypercellular, multilineage dysplasia: 13% blasts, no Auer rods, 12% ring sideroblasts, 4% basophils.

Cyto-Pathology Classification

Cytology

Refractory anemia with excess blasts (RAEB)

Diagnosis

RAEB2 (WHO 2008)

Survival

Date of diagnosis: 01-2013

Treatment: Azacytidine. Blood transfusions were no more needed since.

Complete remission: no

Treatment related death: no

Relapse: no

Status: Alive

Survival: 4 months

Karyotype

Sample: Bone marrow

Culture time: 24h

Banding: BHG

Results

47,XY,+i(4)(p10).ish i(4)(p10)(FRGFR3++, wcp4+)[12] / 47,XY,+8[1]

Other molecular cytogenetics technics

FISH. probe cytoCELL: FGFR3/IGH; ERG1; RELN/TES; ETO/AML1 (RUNX1T1/RUNX1). probe Q-Biogene: wcp4.

Other molecular cytogenetics results

nuc ish 5p15(D5S721,D5S23x2)5q31(ERG1x2)[100] ;
nuc ish 7q22(RELNx2)7q31(TESx2)[100] ; nuc ish
8q22(RUNX1T1x2),21q22(RUNX1x2)[100] ; nuc ish
4p16(FGFR3x4),14q32(IGHx2)[40/50] ; ish
+i(4)4p16(wcp4+,FGFR3+)[3/3]

Comments

We present a new case of isochromosome 4p in a myeloid proliferation. The patient, a 79 years old man developed an MDS (RAEB2), occurring 20 years after an acute myeloid leukemia not otherwise documented. Cytogenetics on bone marrow aspirate revealed a unique abnormality in the karyotype, an additional isochromosome 4p. FISH with wpc4 and FGFR3 probes confirmed the *i(4p)* as an extra chromosome. The most frequent molecular/cytogenetic abnormalities in myeloid proliferations were absent: 5q31, 7q22-q31 probes (for del 5q or del 7q) and ETO + AML1 probes (for +8 or +21) showed no abnormality.

To our knowledge, this is the sixth reported case of myeloid proliferation with an isochromosome 4p as the sole karyotype abnormality. The previous published cases were M4-AML (3 cases), M2-AML (1 case) and RAEB-T (1 case) (Hagemeyer et al., 1981; Hoo et al., 1995; Chen et al., 1999; Soriani et al., 2010). In this short series, only one relapse is recorded after 9 months, it is the unique case of double *i(4p)*; two cases are noted as being in complete remission and two are not documented. The present case is not relevant to the prognosis value of this karyotype anomaly: first, to date the duration of treatment is only three months, but also

the age of the patient, and a previous history of AML are factors which impact the prognosis too greatly by themselves. Isochromosome 4p currently does not have a specific prognostic value in myeloid proliferations.

At the present time, what interpretation of *i(4)(p10)* can be proposed? "Considering that trisomy 4 as the sole abnormality of karyotype is common anomalies in AML and MDS", Chen et al. (1999) suppose that "amplification of genes on 4p but not on 4q may play a crucial role in the pathogenesis of MDS and AML". Recently, two genes located on chromosome 4 were identified as playing a role in myeloid proliferations. In 2003, Dvorak et al. have described the increased expression of FGFR3 (4p16), a member of the family of tyrosine kinase genes, in myeloid proliferating cells of CML and AML. Furthermore TET2 in 4q24 is a putative tumor suppressor in myeloid proliferations (Delhommeau et al., 2009; Jankowska et al., 2009; Vainchenker et al., 2011). Thus it can be assumed that the presence of a supernumerary isochromosome 4p can increase the expression of FGFR3 in 4p16 without increasing the copy number of the tumor suppressor gene TET2 in 4q24.

Call for Collaborations

francoisdesangles@hotmail.com




Figure 1: RHG; partial panel of chromosomes 4 and *i(4)(p10)*.




Figure 2: one metaphase labelled by wpc4: two normal chromosomes 4 and one extra derived chromosome 4.




Figure 3: nuc ish(FGFR3x4,IGHx2); FGFR3 red and IGH green.




Figure 4: two normal chromosomes 4 labelled by an FGFR3 red probe, one extra chromosome labelled by an FGFR3 red probes and two normal chromosomes 14 labelled by an IGH green probe.

References

- Hagemeyer A, Hählen K, Abels J. Cytogenetic follow-up of patients with nonlymphocytic leukemia. II. Acute nonlymphocytic leukemia. *Cancer Genet Cytogenet.* 1981 Mar;3(2):109-24
- Hoo JJ, Gregory SA, Jones B, Szego K. Supernumerary isochromosome 4p in ANLL-M4 myelomonocytic type is associated with favorable prognosis. *Cancer Genet Cytogenet.* 1995 Feb;79(2):127-9
- Chen Z, Richkind K, Roherty S, Velasco J, Lytle C, Brothman AR, Sandberg AA. A group of previously not recognized cytogenetic abnormalities in myeloid hematological malignancies. *Cancer Genet Cytogenet.* 1999 Sep;113(2):162-5
- Dvorak P, Dvorakova D, Doubek M, Faitova J, Pacholikova J, Hampl A, Mayer J. Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia. *Leukemia.* 2003 Dec;17(12):2418-25
- Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Vigué F, Fontenay M, Vainchenker W, Bernard OA. Mutation in TET2 in myeloid cancers. *N Engl J Med.* 2009 May 28;360(22):2289-301
- Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afalse M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA, Maciejewski JP. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. *Blood.* 2009 Jun 18;113(25):6403-10
- Soriani S, Marbello L, Colosimo A, Scarpati B, Grillo G, Cesana C. Double supernumerary isochromosome 4p in acute myelomonocytic leukemia. *Leuk Res.* 2010 Dec;34(12):e342-4
- Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. *Blood.* 2011 Aug 18;118(7):1723-35

This article should be referenced as such:

Desangles F, Servonnet A, Nielly H, Cremades S, Pilo JE. A case of sole *i(4)(p10)* in myelodysplastic syndrome. *Atlas Genet Cytogenet Oncol Haematol.* 2014; 18(2):146-149.
